Category: Commercialization
Launch planning often leans on intuition instead of data about where eligible patients and treating clinicians are.
At launch, teams must decide where to focus, but the segments, accounts, and physicians they prioritize are often chosen on intuition rather than evidence. AI applied to claims and real-world data helps identify patient segments and treating clinicians and prioritize opportunities, giving launch planning a data-grounded starting point that people still interpret and own.
At launch, teams have to decide where to focus — which patient segments, accounts, and clinicians to prioritize — often before real-world uptake data exists. AI applied to claims and other real-world data helps by identifying where eligible patients concentrate, which clinicians are already treating similar patients, and which segments look most relevant, giving planning a data-grounded starting point instead of relying on intuition alone. The output is a set of signals and priorities, not a strategy. Models can reflect patterns in historical data that do not hold at launch, and any targeting has to respect the rules governing how health data and commercial outreach are handled. Treating segments and scores as inputs that people interpret — and that field and compliance teams own — keeps the tool useful without overstating what it can predict.
Start with data representativeness: ask how well the sources cover your population and geography, since segments are only as sound as the data behind them. Then probe transparency — how segments and priority scores are derived, whether the tool can explain them, and how it guards against spurious correlations that look predictive but are not. Because outputs may direct field effort and touch sensitive data, examine privacy safeguards and compliance with the rules on data use and outreach, and confirm the tool integrates with your CRM and planning workflows. Weigh whether its segments are specific and interpretable enough to plan around rather than an opaque ranking a team cannot question.
A practical entry point is to apply the tool to a single indication or geography and compare the segments and priorities it produces against what your team already knows and against any early real-world signals. That shows whether its outputs make commercial and clinical sense, how much they add beyond existing knowledge, and whether they hold up before they drive field deployment or resource decisions.
At launch there is little or no real-world uptake data yet, and the information about where eligible patients and their treating clinicians are is often fragmented across systems. Under time pressure, teams fall back on intuition and prior experience, which can miss where the opportunity actually is.
AI analyzes claims and real-world data to identify patient segments, find clinicians already treating similar patients, and prioritize accounts and geographies where eligible patients concentrate. That gives launch planning a data-grounded starting point rather than one based mainly on intuition.
No. It surfaces data-driven segments and priorities, but historical patterns may not hold at launch, and any targeting has to respect the rules on data use and outreach. The commercial strategy and field decisions are human judgments that people interpret, validate, and own, with the model as one input.
Ask how representative the underlying data is for your population and geography, how segments and priority scores are derived and whether they can be explained, and how the tool guards against spurious correlations. Then examine privacy safeguards and compliance with data-use and outreach rules, and how the tool integrates with your CRM and planning workflows.
Intercept Pharmaceuticals worked with Komodo Health to apply its Healthcare Map real-world data to primary biliary cholangitis, supporting patient-journey and treatment-pattern analyses for its Ocaliva franchise.
Vendor: Komodo Health · press release (Komodo Health (Business Wire)) · 2022-11-10 — Partner: Intercept Pharmaceuticals